ClinicalTrials.gg
RecruitingNCT06073262Updated Oct 10, 2023

Investigation of Low Back Pain Level on Symptoms in Chronic Consipation

An observational study in Low Back Pain and Constipation, sponsored by Istanbul Medipol University Hospital. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Istanbul Medipol University Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
52
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Low Back Pain by Istanbul Medipol University Hospital — 2 open to participants now, 3 under way, none of them phase 3. Low Back Pain · Istanbul Medipol University Hospital.

Started
2023
with 2 others
Observational
2 of 12
2 open now
Registered
4th of 12
by date

Among the 12 studies in Low Back Pain by Istanbul Medipol University Hospital, this one is one of 3 that started in 2023, is one of 2 observational ones, and was the 4th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

2 of the 12 studies in Low Back Pain by Istanbul Medipol University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Low Back Pain by Istanbul Medipol University Hospital, or all of them as a file.
02

Study summary

Consipation is the most common digestive complaint in the general population

Read the detailed description

Chronic constipation and low back pain are two common and often co-existing health conditions that affect millions of people worldwide. On the surface, these conditions appear to be unrelated and are associated with different anatomical sites (gastrointestinal tract and musculoskeletal system). However, a growing body of research is beginning to shed light on the complex interplay between chronic constipation and low back pain, highlighting potential links between these seemingly disparate health conditions. Common etiologic factors such as neuromuscular function, chronic inflammation and lifestyle-related variables are known to exist

03

Conditions studied

  • Low Back Pain
  • Constipation

Keywords

  • pain
  • Low Back Pain
  • Constipation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

In this study, Rome III diagnostic criteria, which is the most commonly used diagnostic method, will be used to determine constipation status. According to the Rome III diagnostic criteria, the following symptoms must have been present for the last 3 months and these symptoms must have started at least 6 months before the diagnosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 ages
  • Rome III diagnostic criteria

Exclusion criteria

Exclusion Criteria:

  • Severe heart or kidney diseaseprevious gastrointestinal, spinal or pelvic surgery other than cholecystectomy, hysterectomy or appendectomy neurological diseases such as
  • Multiple sclerosis, stroke, Parkinson's disease or spinal injury,
  • Impaired awareness (mini-mental score \< 15),
  • Legal blindness, pregnancy,
  • Rectal prolapse
  • Anal fissure and altered constipation and diarrhea pattern.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
52 participants (estimated)
Patient registry
No

Groups and cohorts

  • Non-specific low back pain individual with chronic consipation
  • Individual without low back pain with chronic consipation
06

What researchers measure

Primary outcomes

  1. Bristol Stool Scale

    Lewis and Heaton classified the type of stool in 7 different groups in the scale. In the Bristol Stool Scale, the transit time of stool through the intestine is evaluated over seven different stool types. According to BGS, 1-2 points are shown as "hard stool", 3-4-5 points as "normal stool" and 6-7 points as "soft-watery stool (diarrhea)".

    Time frame: one day

  2. Pelvic Pain Impact Questionnaire

    The questionnaire for clinical assessment of the impact of pelvic pain on women consists of 10 questions. However, the first 8 questions are scored. The range of scores to be obtained from the questionnaire varies between 1- 32. As the score value to be obtained from the questionnaire increases, the degree of functional limitation of pelvic pain on the person increases.

    Time frame: one day

  3. Constipation Severity Scale

    Constipation Severity Scale (CSS) is a scale for determining the frequency, intensity and difficulty/difficulty during defecation. The scale includes 16 questions. The score that can be obtained from the DT sub-dimension is between 0-28, the score that can be obtained from the CBT sub-dimension is between 0-29, and the score that can be obtained from the Pain sub-dimension is between 0-16. The minimum total score that can be obtained from the KCS is 0 and the maximum score is 73. A high score on the scale indicates that the symptoms are serious. The highest score that can be obtained from the five-point Likert-type scale is 140 and the lowest score is 28. It is thought that quality of life is negatively affected as the scores obtained from the scale increase

    Time frame: one day

  4. Disability level

    The Oswestry Disability Index is a commonly used outcome measure to detect perceived disability in patients with low back pain (12). This index consists of 10 items, 8 related to activities of daily living and 2 related to pain. Each item is scored from 0-5 and the total score is expressed as a percentage, with higher scores corresponding to more disability). Increasing scores on the Oswestry Disability Index indicate a higher level of disability.

    Time frame: one day

  5. Autonomic nervous system device (Polar H10)

    The Polar H10 device is a heart rate sensor with the gold standard in high precision and accuracy that comes with a wearable chest strap. It can connect to multiple training devices via Bluetooth and ANT+. The device comes with a soft, adjustable sensor that contacts the chest to capture heart rate in real time. The study will evaluate the autonomic nervous system with the Polar H10 device. The data will be recorded by connecting the device to a smart phone via bluetooth and the software supported by the device will be used to analyze the data. The participant will be in a sitting position and a measurement will be made for 1 minute. In order for the device to make an accurate measurement, the electrode surface must be wetted before each measurement. The subject should not talk or move during the measurement.

    Time frame: one day

07

Study locations

1 of 1 sites recruiting
  • HAZAL genç
    Istanbul, None Selected 34353, Turkey
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2023, 0 months.

Of 177 non-industry observational studies under Low Back Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 0 months is below that.

Counting every sponsor, half of 187 studies reached it within 24 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2023
First posted
Oct 10, 2023
StartActual
Oct 3, 2023
Primary completionActual
Oct 3, 2023
CompletionEst.
Dec 21, 2023
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06073262
Responsible party
hazal genc (Principal Investigator, Istanbul Medipol University Hospital) — Principal investigator
First posted
Oct 10, 2023
Start date
Oct 3, 2023
Primary completion
Oct 3, 2023
Completion
Dec 21, 2023 (estimated)
Last update
Oct 10, 2023

Study contacts

Hazal GENÇ, PhD
Contact
hazaloksuz@gmail.com
05413204291
gamze demircioğlu, PhD
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion